CAMBRIDGE, Mass. – November 26, 2024 -- Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Jeff Jonas, MD will retire from the Company’s Board of Directors as of December 1, 2024. The Company has initiated a search for a new director. Dr. Jonas was CEO at Sage from 2013 to 2020, Chief Innovation Officer from 2020 to 2022, and has served on the Board since 2013.Dr.

。该公司已开始寻找新董事。Jonas博士于2013年至2020年任Sage首席执行官，2020年至2022年任首席创新官，自2013年以来一直担任董事会成员。

Jonas is currently a Partner at Cure Ventures, bringing over two decades of experience in R&D leadership and CNS drug discovery to his role. Before joining Cure, Dr. Jonas was CEO, President, and Director at ABIO-X, a life science incubator focused on transformative medicines. Prior to ABIO-X and Sage Therapeutics, he was President of the Regenerative Medicine Division at Shire Pharmaceuticals, where he directed strategy for marketed products and new pipeline development.

乔纳斯目前是Cure Ventures的合伙人，他在研发领导和中枢神经系统药物发现方面拥有20多年的经验。在加入Cure之前，Jonas博士是ABIO-X的首席执行官、总裁兼董事，ABIO-X是一家专注于变革药物的生命科学孵化器。在加入ABIO-X和Sage Therapeutics之前，他是Shire Pharmaceuticals再生医学部门的总裁，负责指导上市产品和新管道开发的战略。

Earlier in his career, Dr. Jonas was EVP at ISIS (Ionis) Pharmaceuticals and held senior roles at Forest Laboratories and Upjohn.Dr. Jonas has authored over 300 peer-reviewed publications, chapters, and presentations; and holds multiple patents. He earned a BA from Amherst College, an MD from Harvard Medical School, and completed a psychiatry residency at Harvard, where he was Chief Resident of Psychopharmacology at McLean Hospital.

在职业生涯早期，乔纳斯博士曾担任ISIS（Ionis）制药公司的执行总裁，并在森林实验室和Upjohn担任高级职务。乔纳斯博士撰写了300多篇同行评审的出版物、章节和演讲；拥有多项专利。他获得了阿默斯特学院的学士学位，哈佛医学院的医学博士学位，并在哈佛大学完成了精神病学住院治疗，在那里他是麦克莱恩医院的精神药理学首席住院医师。

He currently serves on the board of Generation Bio and is Chairman of Noema Therapeutics and Kenai Therapeutics. .

他目前在生物世代董事会任职，是Noema Therapeutics和Kenai Therapeutics的董事长。。